IXICO
@ixico.bsky.social
A global leader in neuroscience imaging and biomarker analytics, using its proprietary AI-driven platform to help advance the treatment of neurological disorders and reduce the uncertainties associated with drug discovery, development and monitoring.
Today, IXICO announce it has won a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington’s Disease (HD).
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
November 17, 2025 at 7:08 AM
Today, IXICO announce it has won a new commercial contract with a global pharmaceutical company to provide imaging services for a worldwide Phase 3 clinical trial in Huntington’s Disease (HD).
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
We’re attending #CTAD2025 in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
November 11, 2025 at 2:10 PM
We’re attending #CTAD2025 in San Diego (Dec 1–4)!
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
🧠 Poster P173: Harmonization Via Smoothing to A Common Spatial Resolution Yields Modest Benefits in Amyloid PET
📅 Dec 1st (3:00 PM) – Dec 2nd (5:30 PM)
📩 Connect: ixico.com/contact-us
Integrating plasma biomarkers with MRI is reshaping Alzheimer's clinical trials. This dual approach improves enrolment precision, reduces screen failures & boosts efficiency.
Read here:
🔗 ixico.com/news-and-res...
Read here:
🔗 ixico.com/news-and-res...
October 28, 2025 at 4:41 PM
Integrating plasma biomarkers with MRI is reshaping Alzheimer's clinical trials. This dual approach improves enrolment precision, reduces screen failures & boosts efficiency.
Read here:
🔗 ixico.com/news-and-res...
Read here:
🔗 ixico.com/news-and-res...
James Chandler, Chief Business Officer at IXICO, will be at BIO-Europe in Vienna, Austria, on November 3–5!
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
October 23, 2025 at 11:40 AM
James Chandler, Chief Business Officer at IXICO, will be at BIO-Europe in Vienna, Austria, on November 3–5!
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
If you are attending, let's connect!
🔗partneringONE portal: partneringone.informaconnect.com/sign-in?even...
🔗Contact us: www.ixico.com/contact-us
🧠 Happening Tomorrow!
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
October 21, 2025 at 12:01 PM
🧠 Happening Tomorrow!
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
Join us Oct 22 for a deep dive into Alzheimer’s imaging, comorbidities & emerging targets.
🧠 Register now: ixico.com/news-and-res...
Congratulations to Roche Diagnostics USA on receiving FDA clearance for the Elecsys® pTau181 blood test. The first blood test approved for use in primary care to help rule out Alzheimer’s related amyloid pathology.
diagnostics.roche.com/us/en/news-l...
diagnostics.roche.com/us/en/news-l...
October 20, 2025 at 12:10 PM
Congratulations to Roche Diagnostics USA on receiving FDA clearance for the Elecsys® pTau181 blood test. The first blood test approved for use in primary care to help rule out Alzheimer’s related amyloid pathology.
diagnostics.roche.com/us/en/news-l...
diagnostics.roche.com/us/en/news-l...
🧠 IXICO Capital Markets Day
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: ir@cavendish.com
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: ir@cavendish.com
October 17, 2025 at 10:20 AM
🧠 IXICO Capital Markets Day
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: ir@cavendish.com
📅 30 Oct 2025, 14:00–17:00 GMT at Cavendish Capital Markets, London.
Hear from the senior management team, customers & experts on the neuroscience landscape & IXICO’s growth strategy.
📺 www.investormeetcompany.com/ixico-plc/re...
📧 In-person: ir@cavendish.com
IXICO FY25 trading update now live.
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
October 16, 2025 at 6:33 AM
IXICO FY25 trading update now live.
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
Revenue growth, strengthened cash position, and continued momentum.
Read the full RNS on our website: ixico.com/news-and-res...
New contract + AD trial extension for IXICO.
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
October 15, 2025 at 6:07 AM
New contract + AD trial extension for IXICO.
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
Combined value: ~£1.2m
Momentum continues in blood-based biomarkers and Alzheimer’s research.
🔗 Read more: ixico.com/news-and-res...
1 week to go! Discover how imaging is transforming Alzheimer’s disease clinical trials & uncovering new therapeutic paths.
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...
October 14, 2025 at 10:53 AM
1 week to go! Discover how imaging is transforming Alzheimer’s disease clinical trials & uncovering new therapeutic paths.
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...
📅 Oct 22 | 🕔 5pm BST / 6pm CET / 12pm EST
👉 ixico.com/news-and-res...
How do neuroinflammation & vascular pathology shape Alzheimer’s? Find out Oct 22 in our expert-led webinar.
🔗 ixico.com/news-and-res...
🔗 ixico.com/news-and-res...
October 9, 2025 at 2:18 PM
How do neuroinflammation & vascular pathology shape Alzheimer’s? Find out Oct 22 in our expert-led webinar.
🔗 ixico.com/news-and-res...
🔗 ixico.com/news-and-res...
Robin Wolz & Terry Reilly will be at The Michael J Fox Foundations' Parkinson’s Disease Therapeutics Conference on Oct 16.
Catch up with IXICO to explore how imaging & analytics are advancing PD research.
Let’s connect: ixico.com/contact-us
Catch up with IXICO to explore how imaging & analytics are advancing PD research.
Let’s connect: ixico.com/contact-us
October 8, 2025 at 10:39 AM
Robin Wolz & Terry Reilly will be at The Michael J Fox Foundations' Parkinson’s Disease Therapeutics Conference on Oct 16.
Catch up with IXICO to explore how imaging & analytics are advancing PD research.
Let’s connect: ixico.com/contact-us
Catch up with IXICO to explore how imaging & analytics are advancing PD research.
Let’s connect: ixico.com/contact-us
🧠 Tomorrow, we’ll be at ESMRMB2025🧠
Niccolo Fuin and Vahid Malekian will be in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Contact us: ixico.com/contact-us
Niccolo Fuin and Vahid Malekian will be in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Contact us: ixico.com/contact-us
October 7, 2025 at 2:55 PM
🧠 Tomorrow, we’ll be at ESMRMB2025🧠
Niccolo Fuin and Vahid Malekian will be in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Contact us: ixico.com/contact-us
Niccolo Fuin and Vahid Malekian will be in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Contact us: ixico.com/contact-us
IXICO CEO Bram Goorden will be presenting at the Proactive One2One Investor Forum on 9 October 2025 in London, UK
🔗Find out more www.proactiveinvestors.co.uk/register/eve...
🔗Find out more www.proactiveinvestors.co.uk/register/eve...
October 2, 2025 at 11:50 AM
IXICO CEO Bram Goorden will be presenting at the Proactive One2One Investor Forum on 9 October 2025 in London, UK
🔗Find out more www.proactiveinvestors.co.uk/register/eve...
🔗Find out more www.proactiveinvestors.co.uk/register/eve...
Honoured to be recognised at the Precision Medicine Awards 2025 by Oxford Global for our work in precision neuroscience. Huge thanks to our clients, partners, and the brilliant team behind the scenes.
October 2, 2025 at 8:58 AM
Honoured to be recognised at the Precision Medicine Awards 2025 by Oxford Global for our work in precision neuroscience. Huge thanks to our clients, partners, and the brilliant team behind the scenes.
🧠 We’re attending ESMRMB 2025🧠
Niccolo Fuin and Vahid Malekian will be attending the ESMRMB Annual Meeting in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Connect with our team: ixico.com/contact-us
Niccolo Fuin and Vahid Malekian will be attending the ESMRMB Annual Meeting in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Connect with our team: ixico.com/contact-us
October 1, 2025 at 5:17 PM
🧠 We’re attending ESMRMB 2025🧠
Niccolo Fuin and Vahid Malekian will be attending the ESMRMB Annual Meeting in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Connect with our team: ixico.com/contact-us
Niccolo Fuin and Vahid Malekian will be attending the ESMRMB Annual Meeting in Marseille, 8–11 October, joining the MR community to discuss advances in imaging biomarkers and neuroimaging.
Connect with our team: ixico.com/contact-us
Alzheimer’s is more than amyloid & tau. Join experts on Oct 22 to explore imaging, comorbidities & new targets in AD.
🧠 Register: ixico.com/news-and-res...
🧠 Register: ixico.com/news-and-res...
October 1, 2025 at 1:02 PM
Alzheimer’s is more than amyloid & tau. Join experts on Oct 22 to explore imaging, comorbidities & new targets in AD.
🧠 Register: ixico.com/news-and-res...
🧠 Register: ixico.com/news-and-res...
Congratulations to Eli Lilly and Company for another milestone in the fight against Alzheimer’s disease receiving EU marketing authorisation for Kisunla (donanemab).
Read more
investor.lilly.com/news-release...
Read more
investor.lilly.com/news-release...
September 29, 2025 at 5:11 PM
Congratulations to Eli Lilly and Company for another milestone in the fight against Alzheimer’s disease receiving EU marketing authorisation for Kisunla (donanemab).
Read more
investor.lilly.com/news-release...
Read more
investor.lilly.com/news-release...
Huge congrats to uniQure, UCL, and all involved in the AMT-130 trial—showing a 75% slowdown in disease progression over 3 years. Incredible work!
Proud to support this trial at IXICO through neuroimaging + analytics. Let’s keep pushing boundaries.
bbc.co.uk/news/article...
Proud to support this trial at IXICO through neuroimaging + analytics. Let’s keep pushing boundaries.
bbc.co.uk/news/article...
September 25, 2025 at 9:00 AM
Huge congrats to uniQure, UCL, and all involved in the AMT-130 trial—showing a 75% slowdown in disease progression over 3 years. Incredible work!
Proud to support this trial at IXICO through neuroimaging + analytics. Let’s keep pushing boundaries.
bbc.co.uk/news/article...
Proud to support this trial at IXICO through neuroimaging + analytics. Let’s keep pushing boundaries.
bbc.co.uk/news/article...
🧠IXICO at upcoming scientific congresses 🧠
➡️Niccolo Fuin & Vahid Malekian are attending #ESMRMB in Marseille, 8–11 Oct
➡️Kirsi Kinnunen will be at #ESGCT in Seville, 7–10 Oct,
🧠 Connect with us at both events: ixico.com/contact-us
➡️Niccolo Fuin & Vahid Malekian are attending #ESMRMB in Marseille, 8–11 Oct
➡️Kirsi Kinnunen will be at #ESGCT in Seville, 7–10 Oct,
🧠 Connect with us at both events: ixico.com/contact-us
September 24, 2025 at 8:57 PM
🧠IXICO at upcoming scientific congresses 🧠
➡️Niccolo Fuin & Vahid Malekian are attending #ESMRMB in Marseille, 8–11 Oct
➡️Kirsi Kinnunen will be at #ESGCT in Seville, 7–10 Oct,
🧠 Connect with us at both events: ixico.com/contact-us
➡️Niccolo Fuin & Vahid Malekian are attending #ESMRMB in Marseille, 8–11 Oct
➡️Kirsi Kinnunen will be at #ESGCT in Seville, 7–10 Oct,
🧠 Connect with us at both events: ixico.com/contact-us
🧠 Alzheimer’s trial innovation
Join IXICO, Fujirebio & GAP Foundation to explore how blood biomarkers + amyloid PET imaging are transforming AD clinical research.
🎙️ Featuring Robin Wolz, IXICO Chief Scientific & Medical Officer
📅 Oct 9 | 🕒 3:30PM BST / 10:30AM EDT
🔗 events.zoom.us/ev/Apl2Ku3vy...
Join IXICO, Fujirebio & GAP Foundation to explore how blood biomarkers + amyloid PET imaging are transforming AD clinical research.
🎙️ Featuring Robin Wolz, IXICO Chief Scientific & Medical Officer
📅 Oct 9 | 🕒 3:30PM BST / 10:30AM EDT
🔗 events.zoom.us/ev/Apl2Ku3vy...
September 18, 2025 at 2:05 PM
🧠 Alzheimer’s trial innovation
Join IXICO, Fujirebio & GAP Foundation to explore how blood biomarkers + amyloid PET imaging are transforming AD clinical research.
🎙️ Featuring Robin Wolz, IXICO Chief Scientific & Medical Officer
📅 Oct 9 | 🕒 3:30PM BST / 10:30AM EDT
🔗 events.zoom.us/ev/Apl2Ku3vy...
Join IXICO, Fujirebio & GAP Foundation to explore how blood biomarkers + amyloid PET imaging are transforming AD clinical research.
🎙️ Featuring Robin Wolz, IXICO Chief Scientific & Medical Officer
📅 Oct 9 | 🕒 3:30PM BST / 10:30AM EDT
🔗 events.zoom.us/ev/Apl2Ku3vy...
This #WorldAlzheimersMonth, we joined forces with @GAP_Foundation to spotlight how our collaboration is helping accelerate Alzheimer’s research.
Better access. Faster trials. Meaningful insights. Read more about how we’re making a difference: ixico.com/news-and-res...
Better access. Faster trials. Meaningful insights. Read more about how we’re making a difference: ixico.com/news-and-res...
September 18, 2025 at 10:23 AM
This #WorldAlzheimersMonth, we joined forces with @GAP_Foundation to spotlight how our collaboration is helping accelerate Alzheimer’s research.
Better access. Faster trials. Meaningful insights. Read more about how we’re making a difference: ixico.com/news-and-res...
Better access. Faster trials. Meaningful insights. Read more about how we’re making a difference: ixico.com/news-and-res...
World Alzheimer's Disease Awareness Month:
From blood-based biomarkers to gene therapies, Alzheimer’s research is entering a new era—and @IXICO is helping lead the way with AI-powered neuroimaging.
📖 Read our latest blog on innovation trends:
🔗 ixico.com/news-and-res...
From blood-based biomarkers to gene therapies, Alzheimer’s research is entering a new era—and @IXICO is helping lead the way with AI-powered neuroimaging.
📖 Read our latest blog on innovation trends:
🔗 ixico.com/news-and-res...
September 12, 2025 at 10:53 AM
World Alzheimer's Disease Awareness Month:
From blood-based biomarkers to gene therapies, Alzheimer’s research is entering a new era—and @IXICO is helping lead the way with AI-powered neuroimaging.
📖 Read our latest blog on innovation trends:
🔗 ixico.com/news-and-res...
From blood-based biomarkers to gene therapies, Alzheimer’s research is entering a new era—and @IXICO is helping lead the way with AI-powered neuroimaging.
📖 Read our latest blog on innovation trends:
🔗 ixico.com/news-and-res...
September is World Alzheimer’s Month, a time to raise awareness and drive change for the 55 million people living with dementia globally—Alzheimer’s accounts for up to 80% of these cases
🔗 ixico.com/therapeutic-...
🎥 ixico.com/news-and-res...
🔗 ixico.com/therapeutic-...
🎥 ixico.com/news-and-res...
September 5, 2025 at 9:49 AM
September is World Alzheimer’s Month, a time to raise awareness and drive change for the 55 million people living with dementia globally—Alzheimer’s accounts for up to 80% of these cases
🔗 ixico.com/therapeutic-...
🎥 ixico.com/news-and-res...
🔗 ixico.com/therapeutic-...
🎥 ixico.com/news-and-res...
Today IXICO announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications in Alzheimer’s Disease and Friedrich’s Ataxia.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...
August 12, 2025 at 6:01 AM
Today IXICO announced it has signed two separate new commercial contracts to provide neuroimaging services across different core therapeutic indications in Alzheimer’s Disease and Friedrich’s Ataxia.
Read more: ixico.com/news-and-res...
Read more: ixico.com/news-and-res...